The GH/IGF-1 Axis in Growth and Development: New Insights Derived from Animal Models

Advances in Pediatrics

Volumn 57, Issue 1, 2010, Pages 331-351

  Cannata, Dara ^a   Vijayakumar, Archana ^a   Fierz, Yvonne ^a   LeRoith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ANIMAL; BIOMETRY; BODY HEIGHT; BONE DENSITY; BONE DEVELOPMENT; CHILD; CHILD DEVELOPMENT; DISEASE MODEL; GENETICS; GROWTH; GROWTH DISORDER; HUMAN; INFANT; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; BIOMETRY; BODY HEIGHT; BONE DENSITY; BONE DEVELOPMENT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; GROWTH; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR I; MICE; SENSITIVITY AND SPECIFICITY;

EID: 78149366451     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2010.09.003     Document Type: Review

References (150)

1. Rosenfeld R.G. Insulin-like growth factors and the basis of growth. N Engl J Med 2003, 349:2184-2186.
2. Robson H., Siebler T., Shalet S.M., et al. Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth. Pediatr Res 2002, 52:137-147.
3. Yakar S., Rosen C.J., Beamer W.G., et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002, 110:771-781.
4. Tuggle C.K., Trenkle A. Control of growth hormone synthesis. Domest Anim Endocrinol 1996, 13:1-33.
5. Gahete M.D., Duran-Prado M., Luque R.M., et al. Understanding the multifactorial control of growth hormone release by somatotropes: lessons from comparative endocrinology. Ann N Y Acad Sci 2009, 1163:137-153.
6. Pincus S.M., Gevers E.F., Robinson I.C., et al. Females secrete growth hormone with more process irregularity than males in both humans and rats. Am J Physiol 1996, 270:E107-E115.
7. Brazeau P., Vale W., Burgus R., et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179:77-79.
8. Spiess J., Rivier J., Vale W. Characterization of rat hypothalamic growth hormone-releasing factor. Nature 1983, 303:532-535.
9. Spencer S.A., Hammonds R.G., Henzel W.J., et al. Rabbit liver growth hormone receptor and serum binding protein. Purification, characterization, and sequence. J Biol Chem 1988, 263:7862-7867.
10. Baumbach W.R., Horner D.L., Logan J.S. The growth hormone-binding protein in rat serum is an alternatively spliced form of the rat growth hormone receptor. Genes Dev 1989, 3:1199-1205.
11. Smith W.C., Kuniyoshi J., Talamantes F. Mouse serum growth hormone (GH) binding protein has GH receptor extracellular and substituted transmembrane domains. Mol Endocrinol 1989, 3:984-990.
12. Barnard R., Waters M.J. Serum and liver cytosolic growth-hormone-binding proteins are antigenically identical with liver membrane 'receptor' types 1 and 2. Biochem J 1986, 237:885-892.
13. Trivedi B., Daughaday W.H. Release of growth hormone binding protein from IM-9 lymphocytes by endopeptidase is dependent on sulfhydryl group inactivation. Endocrinology 1988, 123:2201-2206.
14. Baumann G., Amburn K., Shaw M.A. The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man. Endocrinology 1988, 122:976-984.
15. Rosenfeld R.G., Rosenbloom A.L., Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994, 15:369-390.
16. Zhou Y., Xu B.C., Maheshwari H.G., et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci U S A 1997, 94:13215-13220.
17. Costa C., Solanes G., Visa J., et al. Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus. FASEB J 1998, 12:1455-1460.
18. Colao A., Merola B., Ferone D., et al. Acromegaly. J Clin Endocrinol Metab 1997, 82:2777-2781.
19. Le Roith D., Bondy C., Yakar S., et al. The somatomedin hypothesis: 2001. Endocr Rev 2001, 22:53-74.
20. LeRoith D., Roberts C.T. Insulin-like growth factors. Ann N Y Acad Sci 1993, 692:1-9.
21. LeRoith D. Insulin-like growth factor receptors and binding proteins. Baillieres Clin Endocrinol Metab 1996, 10:49-73.
22. Clemmons D.R., Busby W., Clarke J.B., et al. Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions. Endocr J 1998, 45(Suppl):S1-S8.
23. Hall L.J., Kajimoto Y., Bichell D., et al. Functional analysis of the rat insulin-like growth factor I gene and identification of an IGF-I gene promoter. DNA Cell Biol 1992, 11:301-313.
24. Bichell D.P., Kikuchi K., Rotwein P. Growth hormone rapidly activates insulin-like growth factor I gene transcription in vivo. Mol Endocrinol 1992, 6:1899-1908.
25. Mathews L.S., Norstedt G., Palmiter R.D. Regulation of insulin-like growth factor I gene expression by growth hormone. Proc Natl Acad Sci U S A 1986, 83:9343-9347.
26. Pell J.M., Saunders J.C., Gilmour R.S. Differential regulation of transcription initiation from insulin-like growth factor-I (IGF-I) leader exons and of tissue IGF-I expression in response to changed growth hormone and nutritional status in sheep. Endocrinology 1993, 132:1797-1807.
27. Yamashita S., Melmed S. Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells. J Clin Invest 1987, 79:449-452.
28. Yamashita S., Ong J., Melmed S. Regulation of human growth hormone gene expression by insulin-like growth factor I in transfected cells. J Biol Chem 1987, 262:13254-13257.
29. Nilsson O., Marino R., De Luca F., et al. Endocrine regulation of the growth plate. Horm Res 2005, 64:157-165.
30. Kember N.F. Cell population kinetics of bone growth: the first ten years of autoradiographic studies with tritiated thymidine. Clin Orthop Relat Res 1971, 76:213-230.
31. Abad V., Meyers J.L., Weise M., et al. The role of the resting zone in growth plate chondrogenesis. Endocrinology 2002, 143:1851-1857.
32. Hunziker E.B., Wagner J., Zapf J. Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo. J Clin Invest 1994, 93:1078-1086.
33. Weise M., De-Levi S., Barnes K.M., et al. Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc Natl Acad Sci U S A 2001, 98:6871-6876.
34. Wang Q., Seeman E. Skeletal growth and peak bone strength. Best Pract Res Clin Endocrinol Metab 2008, 22:687-700.
35. Tritos N.A., Biller B.M. Growth hormone and bone. Curr Opin Endocrinol Diabetes Obes 2009, 16:415-422.
36. Bonjour J.P., Theintz G., Law F., et al. Peak bone mass. Osteoporos Int 1994, 4(Suppl 1):7-13.
37. Salmon W.D., Daughaday W.H. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957, 49:825-836.
38. Murphy W.R., Daughaday W.H., Hartnett C. The effect of hypophysectomy and growth hormone on the incorporation of labeled sulfate into tibial epiphyseal and nasal cartilage of the rat. J Lab Clin Med 1956, 47:715-722.
39. Denko C.W., Bergenstal D.M. The effect of hypophysectomy and growth hormone on S35 fixation in cartilage. Endocrinology 1955, 57:76-86.
40. Daughaday W.H., Reeder C. Synchronous activation of DNA synthesis in hypophysectomized rat cartilage by growth hormone. J Lab Clin Med 1966, 68:357-368.
41. Daughaday W.H., Hall K., Raben M.S., et al. Somatomedin: proposed designation for sulphation factor. Nature 1972, 235:107.
42. Rinderknecht E., Humbel R.E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978, 253:2769-2776.
43. D'Ercole A.J., Applewhite G.T., Underwood L.E. Evidence that somatomedin is synthesized by multiple tissues in the fetus. Dev Biol 1980, 75:315-328.
44. Isaksson O.G., Jansson J.O., Gause I.A. Growth hormone stimulates longitudinal bone growth directly. Science 1982, 216:1237-1239.
45. Green H., Morikawa M., Nixon T. A dual effector theory of growth-hormone action. Differentiation 1985, 29:195-198.
46. Isaksson O.G., Lindahl A., Nilsson A., et al. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 1987, 8:426-438.
47. Ohlsson C., Nilsson A., Isaksson O., et al. Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plate. Proc Natl Acad Sci U S A 1992, 89:9826-9830.
48. Shinar D.M., Endo N., Halperin D., et al. Differential expression of insulin-like growth factor-I (IGF-I) and IGF-II messenger ribonucleic acid in growing rat bone. Endocrinology 1993, 132:1158-1167.
49. Wang E., Wang J., Chin E., et al. Cellular patterns of insulin-like growth factor system gene expression in murine chondrogenesis and osteogenesis. Endocrinology 1995, 136:2741-2751.
50. Wang J., Zhou J., Bondy C.A. Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy. FASEB J 1999, 13:1985-1990.
51. Lupu F., Terwilliger J.D., Lee K., et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001, 229:141-162.
52. Mohan S., Richman C., Guo R., et al. Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms. Endocrinology 2003, 144:929-936.
53. Wang Y., Nishida S., Sakata T., et al. Insulin-like growth factor-I is essential for embryonic bone development. Endocrinology 2006, 147:4753-4761.
54. Hutchison M.R., Bassett M.H., White P.C. Insulin-like growth factor-I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation. Endocrinology 2007, 148:3122-3130.
55. Kaplan S.A., Cohen P. The somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab 2007, 92:4529-4535.
56. Boguszewski C.L., Svensson P.A., Jansson T., et al. Cloning of two novel growth hormone transcripts expressed in human placenta. J Clin Endocrinol Metab 1998, 83:2878-2885.
57. Mol J.A., Henzen-Logmans S.C., Hageman P., et al. Expression of the gene encoding growth hormone in the human mammary gland. J Clin Endocrinol Metab 1995, 80:3094-3096.
58. de Mello-Coelho V., Gagnerault M.C., Souberbielle J.C., et al. Growth hormone and its receptor are expressed in human thymic cells. Endocrinology 1998, 139:3837-3842.
59. Kooijman R., Berus D., Malur A., et al. Human neutrophils express GH-N gene transcripts and the pituitary transcription factor Pit-1b. Endocrinology 1997, 138:4481-4484.
60. Berry S.A., Srivastava C.H., Rubin L.R., et al. Growth hormone-releasing hormone-like messenger ribonucleic acid and immunoreactive peptide are present in human testis and placenta. J Clin Endocrinol Metab 1992, 75:281-284.
61. Mertani H.C., Waters M.J., Jambou R., et al. Growth hormone receptor binding protein in rat anterior pituitary. Neuroendocrinology 1994, 59:483-494.
62. Kojima M., Hosoda H., Date Y., et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
63. Tannenbaum G.S., Gurd W., Lapointe M. Leptin is a potent stimulator of spontaneous pulsatile growth hormone (GH) secretion and the GH response to GH-releasing hormone. Endocrinology 1998, 139:3871-3875.
64. Imaki T., Shibasaki T., Shizume K., et al. The effect of free fatty acids on growth hormone (GH)-releasing hormone-mediated GH secretion in man. J Clin Endocrinol Metab 1985, 60:290-293.
65. Herber S.M., Milner R.D. Growth hormone deficiency presenting under age 2 years. Arch Dis Child 1984, 59:557-560.
66. Lichanska A.M., Waters M.J. How growth hormone controls growth, obesity and sexual dimorphism. Trends Genet 2008, 24:41-47.
67. Kopchick J.J., Andry J.M. Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab 2000, 71:293-314.
68. Rosenfeld R.G., Hwa V. The growth hormone cascade and its role in mammalian growth. Horm Res 2009, 71(Suppl 2):36-40.
69. Gent J., van Kerkhof P., Roza M., et al. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci U S A 2002, 99:9858-9863.
70. Goffin V., Kelly P.A. The prolactin/growth hormone receptor family: structure/function relationships. J Mammary Gland Biol Neoplasia 1997, 2:7-17.
71. Yang N., Wang X., Jiang J., et al. Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Mol Endocrinol 2007, 21:1642-1655.
72. Argetsinger L.S., Campbell G.S., Yang X., et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 1993, 74:237-244.
73. Hansen J.A., Lindberg K., Hilton D.J., et al. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol Endocrinol 1999, 13:1832-1843.
74. Udy G.B., Towers R.P., Snell R.G., et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 1997, 94:7239-7244.
75. Teglund S., McKay C., Schuetz E., et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998, 93:841-850.
76. Chia D.J., Ono M., Woelfle J., et al. Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription. J Biol Chem 2006, 281:3190-3197.
77. Rosenfeld R.G., Belgorosky A., Camacho-Hubner C., et al. Defects in growth hormone receptor signaling. Trends Endocrinol Metab 2007, 18:134-141.
78. Kofoed E.M., Hwa V., Little B., et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003, 349:1139-1147.
79. Saltiel A.R., Kahn C.R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
80. Eicher E.M., Beamer W.G. Inherited ateliotic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6. J Hered 1976, 67:87-91.
81. Eicher E.M., Beamer W.G. New mouse dw allele: genetic location and effects on lifespan and growth hormone levels. J Hered 1980, 71:187-190.
82. Bartke A. Histology of the anterior hypophysis, thyroid and gonads of two types of dwarf mice. Anat Rec 1964, 149:225-235.
83. Bartke A. The response of two types of dwarf mice to growth hormone, thyrotropin, and thyroxine. Gen Comp Endocrinol 1965, 5:418-426.
84. Beamer W.H., Eicher E.M. Stimulation of growth in the little mouse. J Endocrinol 1976, 71:37-45.
85. Bartke A., Goldman B.D., Bex F., et al. Effects of prolactin (PRL) on pituitary and testicular function in mice with hereditary PRL deficiency. Endocrinology 1977, 101:1760-1766.
86. Brown-Borg H.M., Borg K.E., Meliska C.J., et al. Dwarf mice and the ageing process. Nature 1996, 384:33.
87. Flurkey K., Papaconstantinou J., Miller R.A., et al. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc Natl Acad Sci U S A 2001, 98:6736-6741.
88. Lin S.C., Lin C.R., Gukovsky I., et al. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature 1993, 364:208-213.
89. Cheng T.C., Beamer W.G., Phillips J.A., et al. Etiology of growth hormone deficiency in little, Ames, and Snell dwarf mice. Endocrinology 1983, 113:1669-1678.
90. Donahue L.R., Beamer W.G. Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. J Endocrinol 1993, 136:91-104.
91. Kopchick J.J., Laron Z. Is the Laron mouse an accurate model of Laron syndrome?. Mol Genet Metab 1999, 68:232-236.
92. Craft W.H., Underwoood L.E., Van Wyk J.J. High incidence of perinatal insult in children with idiopathic hypopituitarism. J Pediatr 1980, 96:397-402.
93. Gluckman P.D., Gunn A.J., Wray A., et al. Congenital idiopathic growth hormone deficiency associated with prenatal and early postnatal growth failure. The International Board of the Kabi Pharmacia International Growth Study. J Pediatr 1992, 121:920-923.
94. De Luca F., Bernasconi S., Blandino A., et al. Auxological, clinical and neuroradiological findings in infants with early onset growth hormone deficiency. Acta Paediatr 1995, 84:561-565.
95. Pena-Almazan S., Buchlis J., Miller S., et al. Linear growth characteristics of congenitally GH-deficient infants from birth to one year of age. J Clin Endocrinol Metab 2001, 86:5691-5694.
96. Saggese G., Baroncelli G.I., Bertelloni S., et al. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab 1996, 81:3077-3083.
97. Saggese G., Baroncelli G.I., Bertelloni S., et al. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 1993, 122:37-45.
98. Laron Z., Pertzelan A., Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone-a new inborn error of metabolism?. Isr J Med Sci 1966, 2:152-155.
99. Woods K.A., Savage M.O. Laron syndrome: typical and atypical forms. Baillieres Clin Endocrinol Metab 1996, 10:371-387.
100. Baumann G., Shaw M.A., Winter R.J. Absence of the plasma growth hormone-binding protein in Laron-type dwarfism. J Clin Endocrinol Metab 1987, 65:814-816.
101. Daughaday W.H., Trivedi B. Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism). Proc Natl Acad Sci U S A 1987, 84:4636-4640.
102. Laron Z., Klinger B., Erster B., et al. Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism. Acta Endocrinol (Copenh) 1989, 121:603-608.
103. Amselem S., Duquesnoy P., Duriez B., et al. Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome. Hum Mol Genet 1993, 2:355-359.
104. Rosenbloom A.L., Guevara Aguirre J., Rosenfeld R.G., et al. The little women of Loja-growth hormone-receptor deficiency in an inbred population of southern Ecuador. N Engl J Med 1990, 323:1367-1374.
105. Rosenbloom A.L., Guevara-Aguirre J., Rosenfeld R.G., et al. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab 1999, 84:4436-4443.
106. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004, 89:1031-1044.
107. Kornreich L., Horev G., Schwarz M., et al. Laron syndrome abnormalities: spinal stenosis, os odontoideum, degenerative changes of the atlanto-odontoid joint, and small oropharynx. AJNR Am J Neuroradiol 2002, 23:625-631.
108. Laron Z., Klinger B. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin Endocrinol (Oxf) 1994, 41:631-638.
109. Bachrach L.K., Marcus R., Ott S.M., et al. Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. J Bone Miner Res 1998, 13:415-421.
110. Carel J.C., Chaussain J.L., Chatelain P., et al. Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment. Diabetes Metab 1996, 22:251-256.
111. Palmiter R.D., Brinster R.L., Hammer R.E., et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 1982, 300:611-615.
112. Knapp J.R., Chen W.Y., Turner N.D., et al. Growth patterns and body composition of transgenic mice expressing mutated bovine somatotropin genes. J Anim Sci 1994, 72:2812-2819.
113. McGrane M.M., de Vente J., Yun J., et al. Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice. J Biol Chem 1988, 263:11443-11451.
114. Eckstein F., Lochmuller E.M., Koller B., et al. Body composition, bone mass and microstructural analysis in GH-transgenic mice reveals that skeletal changes are specific to bone compartment and gender. Growth Horm IGF Res 2002, 12:116-125.
115. Callewaert F., Venken K., Kopchick J.J., et al. Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-I: evidence from pubertal mouse models. J Bone Miner Res 2010, 25:617-626.
116. Melmed S. Medical progress: acromegaly. N Engl J Med 2006, 355:2558-2573.
117. Keil M.F., Stratakis C.A. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother 2008, 8:563-574.
118. Katznelson L. Alterations in body composition in acromegaly. Pituitary 2009, 12:136-142.
119. Diamond T., Nery L., Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 1989, 111:567-573.
120. Colao A., Pivonello R., Scarpa R., et al. The acromegalic arthropathy. J Endocrinol Invest 2005, 28:24-31.
121. Vestergaard P., Mosekilde L. Fracture risk is decreased in acromegaly-a potential beneficial effect of growth hormone. Osteoporos Int 2004, 15:155-159.
122. Ullrich A., Gray A., Tam A.W., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986, 5:2503-2512.
123. Steele-Perkins G., Turner J., Edman J.C., et al. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 1988, 263:11486-11492.
124. Sasaki N., Rees-Jones R.W., Zick Y., et al. Characterization of insulin-like growth factor I-stimulated tyrosine kinase activity associated with the beta-subunit of type I insulin-like growth factor receptors of rat liver cells. J Biol Chem 1985, 260:9793-9804.
125. Bianda T., Hussain M.A., Glatz Y., et al. Effects of short-term insulin-like growth factor-I or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1,25 dihydroxyvitamin D3 production in healthy man. J Intern Med 1997, 241:143-150.
126. Mauras N., Doi S.Q., Shapiro J.R. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans. J Clin Endocrinol Metab 1996, 81:2222-2226.
127. Liu J.P., Baker J., Perkins A.S., et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75:59-72.
128. Woods K.A., Camacho-Hubner C., Savage M.O., et al. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996, 335:1363-1367.
129. Abuzzahab M.J., Schneider A., Goddard A., et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003, 349:2211-2222.
130. Baker J., Liu J.P., Robertson E.J., et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75:73-82.
131. Liu J.L., Grinberg A., Westphal H., et al. Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice. Mol Endocrinol 1998, 12:1452-1462.
132. Mohan S., Baylink D.J. Impaired skeletal growth in mice with haploinsufficiency of IGF-I: genetic evidence that differences in IGF-I expression could contribute to peak bone mineral density differences. J Endocrinol 2005, 185:415-420.
133. DeChiara T.M., Efstratiadis A., Robertson E.J. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990, 345:78-80.
134. Zhao G., Monier-Faugere M.C., Langub M.C., et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 2000, 141:2674-2682.
135. Baylink D., Lau K.H., Mohan S. The role of IGF system in the rise and fall in bone density with age. J Musculoskelet Neuronal Interact 2007, 7:304-305.
136. Adami S., Zivelonghi A., Braga V., et al. Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women. Bone 2010, 46:244-247.
137. Thompson J.L., Butterfield G.E., Gylfadottir U.K., et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab 1998, 83:1477-1484.
138. Butterfield G.E., Thompson J., Rennie M.J., et al. Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am J Physiol 1997, 272:E94-E99.
139. Walenkamp M.J., Karperien M., Pereira A.M., et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005, 90:2855-2864.
140. Bonapace G., Concolino D., Formicola S., et al. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 2003, 40:913-917.
141. Kawashima Y., Kanzaki S., Yang F., et al. Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab 2005, 90:4679-4687.
142. Domene H.M., Hwa V., Argente J., et al. Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 2009, 72:129-141.
143. van Duyvenvoorde H.A., Kempers M.J., Twickler T.B., et al. Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol 2008, 159:113-120.
144. Lowe W.L., Roberts C.T., Lasky S.R., et al. Differential expression of alternative 5' untranslated regions in mRNAs encoding rat insulin-like growth factor I. Proc Natl Acad Sci U S A 1987, 84:8946-8950.
145. Lowe W.L., Lasky S.R., LeRoith D., et al. Distribution and regulation of rat insulin-like growth factor I messenger ribonucleic acids encoding alternative carboxy terminal E-peptides: evidence for differential processing and regulation in liver. Mol Endocrinol 1988, 2:528-535.
146. Murphy L.J., Bell G.I., Friesen H.G. Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology 1987, 120:1279-1282.
147. Yakar S., Liu J.L., Stannard B., et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999, 96:7324-7329.
148. Ueki I., Ooi G.T., Tremblay M.L., et al. Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system. Proc Natl Acad Sci U S A 2000, 97:6868-6873.
149. Stratikopoulos E., Szabolcs M., Dragatsis I., et al. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci U S A 2008, 105:19378-19383.
150. Wu Y., Sun H., Yakar S., et al. Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology 2009, 150:4395-4403.